<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>寶血純化科技-BLUE BLOOD</title>
	<atom:link href="https://blueblood.com.tw/th/feed/" rel="self" type="application/rss+xml" />
	<link>https://blueblood.com.tw</link>
	<description>寶血純化專注於蛋白質新藥研發，擁有卓越的蛋白質純化、分析及 DNA 重組技術。核心產品 BB-101 可促進糖尿病傷口癒合，目前正進行第二期臨床試驗。我們致力於推動生物製藥發展，與產業界及學術界合作，以科學創新為基礎，期望為患者提供更有效且安全的醫療保健解決方案，改善全球健康福祉。</description>
	<lastBuildDate>Mon, 15 Sep 2025 08:35:23 +0000</lastBuildDate>
	<language>th</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=5.8.12</generator>

<image>
	<url>https://blueblood.com.tw/wp-content/uploads/2025/08/favicon-up-80x80.png</url>
	<title>寶血純化科技-BLUE BLOOD</title>
	<link>https://blueblood.com.tw</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>แผ่นไมโครนีดเดิลแบบละลายน้ำได้รับสิทธิบัตรรูปแบบอรรถประโยชน์ของไต้หวัน</title>
		<link>https://blueblood.com.tw/th/%e5%8f%af%e6%ba%b6%e5%bc%8f%e5%be%ae%e9%87%9d%e8%b2%bc%e7%89%87%e5%8f%96%e5%be%97%e4%b8%ad%e8%8f%af%e6%b0%91%e5%9c%8b%e6%96%b0%e5%9e%8b%e5%b0%88%e5%88%a9/</link>
		
		<dc:creator><![CDATA[simon]]></dc:creator>
		<pubDate>Fri, 21 Mar 2025 03:05:14 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.com.tw/?p=2297</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>สูตรและวิธีสำหรับรักษาการหลุดร่วงของเส้นผมหรือส่งเสริมการเจริญเติบโตของเส้นผม ได้รับสิทธิบัตรของไต้หวัน</title>
		<link>https://blueblood.com.tw/th/%e6%b2%bb%e7%99%82%e8%90%bd%e9%ab%ae%e6%88%96%e4%bf%83%e9%80%b2%e6%af%9b%e9%ab%ae%e7%94%9f%e9%95%b7%e7%9a%84%e7%b5%84%e6%88%90%e7%89%a9%e5%8f%8a%e6%96%b9%e6%b3%95%e7%8d%b2%e5%87%86%e4%b8%ad%e8%8f%af/</link>
		
		<dc:creator><![CDATA[simon]]></dc:creator>
		<pubDate>Sat, 01 Mar 2025 03:17:28 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.com.tw/?p=2306</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>แผ่นไมโครนีดเดิลชนิดละลายได้ ได้ผ่านการศึกษาทางคลินิกด้านเครื่องสำอางในประเทศเกาหลี</title>
		<link>https://blueblood.com.tw/th/%e5%8f%af%e6%ba%b6%e5%bc%8f%e5%be%ae%e9%87%9d%e8%b2%bc%e7%89%87%e5%9c%a8%e9%9f%93%e5%9c%8b%e5%ae%8c%e6%88%90%e5%8c%96%e5%a6%9d%e5%93%81%e8%87%a8%e5%ba%8a%e7%a0%94%e7%a9%b6/</link>
		
		<dc:creator><![CDATA[simon]]></dc:creator>
		<pubDate>Wed, 15 Jan 2025 08:35:12 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<guid isPermaLink="false">https://blueblood.com.tw/?p=2383</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>สำเร็จการผลิตผลิตภัณฑ์ไมโครนีดเดิลที่สามารถละลายได้</title>
		<link>https://blueblood.com.tw/th/%e0%b8%aa%e0%b8%b3%e0%b9%80%e0%b8%a3%e0%b9%87%e0%b8%88%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%9c%e0%b8%a5%e0%b8%b4%e0%b8%95%e0%b8%9c%e0%b8%a5%e0%b8%b4%e0%b8%95%e0%b8%a0%e0%b8%b1%e0%b8%93%e0%b8%91%e0%b9%8c/</link>
		
		<dc:creator><![CDATA[agent30]]></dc:creator>
		<pubDate>Sat, 01 Jun 2024 04:00:36 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.morcept.tw/?p=1765</guid>

					<description><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing eli [&#8230;]</p>
<p>The post <a href="https://blueblood.com.tw/th/%e0%b8%aa%e0%b8%b3%e0%b9%80%e0%b8%a3%e0%b9%87%e0%b8%88%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%9c%e0%b8%a5%e0%b8%b4%e0%b8%95%e0%b8%9c%e0%b8%a5%e0%b8%b4%e0%b8%95%e0%b8%a0%e0%b8%b1%e0%b8%93%e0%b8%91%e0%b9%8c/">สำเร็จการผลิตผลิตภัณฑ์ไมโครนีดเดิลที่สามารถละลายได้</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></description>
										<content:encoded><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.</p>
<ul>
<li>In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.</li>
<li>Nullam dictum felis eu pede mollis pretium.</li>
<li>Integer tincidunt.</li>
</ul>
<p>Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.</p>
<blockquote><p>Nam eget dui.</p></blockquote>
<p>Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.</p><p>The post <a href="https://blueblood.com.tw/th/%e0%b8%aa%e0%b8%b3%e0%b9%80%e0%b8%a3%e0%b9%87%e0%b8%88%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%9c%e0%b8%a5%e0%b8%b4%e0%b8%95%e0%b8%9c%e0%b8%a5%e0%b8%b4%e0%b8%95%e0%b8%a0%e0%b8%b1%e0%b8%93%e0%b8%91%e0%b9%8c/">สำเร็จการผลิตผลิตภัณฑ์ไมโครนีดเดิลที่สามารถละลายได้</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ผ่านการประเมินมูลค่าจดสิทธิบัตรและขึ้นทะเบียนเทคโนโลยีการรักษาผมร่วงจากฮอร์โมนแอนโดรเจน แก่ Sanar Biotech Corp.</title>
		<link>https://blueblood.com.tw/th/%e0%b8%9c%e0%b9%88%e0%b8%b2%e0%b8%99%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%9b%e0%b8%a3%e0%b8%b0%e0%b9%80%e0%b8%a1%e0%b8%b4%e0%b8%99%e0%b8%a1%e0%b8%b9%e0%b8%a5%e0%b8%84%e0%b9%88%e0%b8%b2%e0%b8%88%e0%b8%94/</link>
		
		<dc:creator><![CDATA[agent30]]></dc:creator>
		<pubDate>Wed, 01 May 2024 04:00:53 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.morcept.tw/?p=1768</guid>

					<description><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing eli [&#8230;]</p>
<p>The post <a href="https://blueblood.com.tw/th/%e0%b8%9c%e0%b9%88%e0%b8%b2%e0%b8%99%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%9b%e0%b8%a3%e0%b8%b0%e0%b9%80%e0%b8%a1%e0%b8%b4%e0%b8%99%e0%b8%a1%e0%b8%b9%e0%b8%a5%e0%b8%84%e0%b9%88%e0%b8%b2%e0%b8%88%e0%b8%94/">ผ่านการประเมินมูลค่าจดสิทธิบัตรและขึ้นทะเบียนเทคโนโลยีการรักษาผมร่วงจากฮอร์โมนแอนโดรเจน แก่ Sanar Biotech Corp.</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></description>
										<content:encoded><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.</p>
<ul>
<li>In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.</li>
<li>Nullam dictum felis eu pede mollis pretium.</li>
<li>Integer tincidunt.</li>
</ul>
<p>Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.</p>
<blockquote><p>Nam eget dui.</p></blockquote>
<p>Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.</p><p>The post <a href="https://blueblood.com.tw/th/%e0%b8%9c%e0%b9%88%e0%b8%b2%e0%b8%99%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%9b%e0%b8%a3%e0%b8%b0%e0%b9%80%e0%b8%a1%e0%b8%b4%e0%b8%99%e0%b8%a1%e0%b8%b9%e0%b8%a5%e0%b8%84%e0%b9%88%e0%b8%b2%e0%b8%88%e0%b8%94/">ผ่านการประเมินมูลค่าจดสิทธิบัตรและขึ้นทะเบียนเทคโนโลยีการรักษาผมร่วงจากฮอร์โมนแอนโดรเจน แก่ Sanar Biotech Corp.</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>การทดลองทางคลินิกระยะที่ 2 ของ BB-101 ได้รับการอนุมัติจากกระทรวงเศรษฐกิจการค้าแห่งไต้หวัน พร้อมได้รับเงินอุดหนุนจำนวน 34 ล้านดอลลาร์ไต้หวัน ภายใต้โครงการ ‘A+ Enterprise Innovation R&#038;D Program – Fast-Track Clinical Trial Review’</title>
		<link>https://blueblood.com.tw/th/%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%97%e0%b8%94%e0%b8%a5%e0%b8%ad%e0%b8%87%e0%b8%97%e0%b8%b2%e0%b8%87%e0%b8%84%e0%b8%a5%e0%b8%b4%e0%b8%99%e0%b8%b4%e0%b8%81%e0%b8%a3%e0%b8%b0%e0%b8%a2%e0%b8%b0%e0%b8%97-2/</link>
		
		<dc:creator><![CDATA[agent30]]></dc:creator>
		<pubDate>Mon, 01 Jan 2024 04:00:02 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.morcept.tw/?p=1771</guid>

					<description><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing eli [&#8230;]</p>
<p>The post <a href="https://blueblood.com.tw/th/%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%97%e0%b8%94%e0%b8%a5%e0%b8%ad%e0%b8%87%e0%b8%97%e0%b8%b2%e0%b8%87%e0%b8%84%e0%b8%a5%e0%b8%b4%e0%b8%99%e0%b8%b4%e0%b8%81%e0%b8%a3%e0%b8%b0%e0%b8%a2%e0%b8%b0%e0%b8%97-2/">การทดลองทางคลินิกระยะที่ 2 ของ BB-101 ได้รับการอนุมัติจากกระทรวงเศรษฐกิจการค้าแห่งไต้หวัน พร้อมได้รับเงินอุดหนุนจำนวน 34 ล้านดอลลาร์ไต้หวัน ภายใต้โครงการ ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review’</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></description>
										<content:encoded><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.</p>
<ul>
<li>In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.</li>
<li>Nullam dictum felis eu pede mollis pretium.</li>
<li>Integer tincidunt.</li>
</ul>
<p>Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.</p>
<blockquote><p>Nam eget dui.</p></blockquote>
<p>Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.</p><p>The post <a href="https://blueblood.com.tw/th/%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%97%e0%b8%94%e0%b8%a5%e0%b8%ad%e0%b8%87%e0%b8%97%e0%b8%b2%e0%b8%87%e0%b8%84%e0%b8%a5%e0%b8%b4%e0%b8%99%e0%b8%b4%e0%b8%81%e0%b8%a3%e0%b8%b0%e0%b8%a2%e0%b8%b0%e0%b8%97-2/">การทดลองทางคลินิกระยะที่ 2 ของ BB-101 ได้รับการอนุมัติจากกระทรวงเศรษฐกิจการค้าแห่งไต้หวัน พร้อมได้รับเงินอุดหนุนจำนวน 34 ล้านดอลลาร์ไต้หวัน ภายใต้โครงการ ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review’</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ยา BB-101 ได้รับการอนุมัติจากองค์การอาหารและยาของไต้หวัน (Taiwan FDA) สำหรับการทดลองทางคลินิก และเริ่มการทดลองทางคลินิกระยะที่ 2 ที่ศูนย์การแพทย์ 3 แห่งในไต้หวัน</title>
		<link>https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b2-bb-101-%e0%b9%84%e0%b8%94%e0%b9%89%e0%b8%a3%e0%b8%b1%e0%b8%9a%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%a1%e0%b8%b1%e0%b8%95%e0%b8%b4%e0%b8%88%e0%b8%b2%e0%b8%81/</link>
		
		<dc:creator><![CDATA[agent30]]></dc:creator>
		<pubDate>Thu, 01 Jun 2023 04:00:56 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.morcept.tw/?p=1774</guid>

					<description><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing eli [&#8230;]</p>
<p>The post <a href="https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b2-bb-101-%e0%b9%84%e0%b8%94%e0%b9%89%e0%b8%a3%e0%b8%b1%e0%b8%9a%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%a1%e0%b8%b1%e0%b8%95%e0%b8%b4%e0%b8%88%e0%b8%b2%e0%b8%81/">ยา BB-101 ได้รับการอนุมัติจากองค์การอาหารและยาของไต้หวัน (Taiwan FDA) สำหรับการทดลองทางคลินิก และเริ่มการทดลองทางคลินิกระยะที่ 2 ที่ศูนย์การแพทย์ 3 แห่งในไต้หวัน</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></description>
										<content:encoded><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.</p>
<ul>
<li>In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.</li>
<li>Nullam dictum felis eu pede mollis pretium.</li>
<li>Integer tincidunt.</li>
</ul>
<p>Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.</p>
<blockquote><p>Nam eget dui.</p></blockquote>
<p>Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.</p><p>The post <a href="https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b2-bb-101-%e0%b9%84%e0%b8%94%e0%b9%89%e0%b8%a3%e0%b8%b1%e0%b8%9a%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%a1%e0%b8%b1%e0%b8%95%e0%b8%b4%e0%b8%88%e0%b8%b2%e0%b8%81/">ยา BB-101 ได้รับการอนุมัติจากองค์การอาหารและยาของไต้หวัน (Taiwan FDA) สำหรับการทดลองทางคลินิก และเริ่มการทดลองทางคลินิกระยะที่ 2 ที่ศูนย์การแพทย์ 3 แห่งในไต้หวัน</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ยื่นขออนุญาตต่อองค์การอาหารและยาของไต้หวัน เพื่อดำเนินการทดลองทางคลินิกระยะที่ 2 ของยา BB-101</title>
		<link>https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b7%e0%b9%88%e0%b8%99%e0%b8%82%e0%b8%ad%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%8d%e0%b8%b2%e0%b8%95%e0%b8%95%e0%b9%88%e0%b8%ad%e0%b8%ad%e0%b8%87%e0%b8%84%e0%b9%8c%e0%b8%81%e0%b8%b2%e0%b8%a3/</link>
		
		<dc:creator><![CDATA[agent30]]></dc:creator>
		<pubDate>Wed, 01 Mar 2023 04:00:45 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.morcept.tw/?p=1777</guid>

					<description><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing eli [&#8230;]</p>
<p>The post <a href="https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b7%e0%b9%88%e0%b8%99%e0%b8%82%e0%b8%ad%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%8d%e0%b8%b2%e0%b8%95%e0%b8%95%e0%b9%88%e0%b8%ad%e0%b8%ad%e0%b8%87%e0%b8%84%e0%b9%8c%e0%b8%81%e0%b8%b2%e0%b8%a3/">ยื่นขออนุญาตต่อองค์การอาหารและยาของไต้หวัน เพื่อดำเนินการทดลองทางคลินิกระยะที่ 2 ของยา BB-101</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></description>
										<content:encoded><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.</p>
<ul>
<li>In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.</li>
<li>Nullam dictum felis eu pede mollis pretium.</li>
<li>Integer tincidunt.</li>
</ul>
<p>Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.</p>
<blockquote><p>Nam eget dui.</p></blockquote>
<p>Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.</p><p>The post <a href="https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b7%e0%b9%88%e0%b8%99%e0%b8%82%e0%b8%ad%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%8d%e0%b8%b2%e0%b8%95%e0%b8%95%e0%b9%88%e0%b8%ad%e0%b8%ad%e0%b8%87%e0%b8%84%e0%b9%8c%e0%b8%81%e0%b8%b2%e0%b8%a3/">ยื่นขออนุญาตต่อองค์การอาหารและยาของไต้หวัน เพื่อดำเนินการทดลองทางคลินิกระยะที่ 2 ของยา BB-101</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ยื่นขออนุญาตต่อองค์การอาหารและยาของสหรัฐอเมริกา (US FDA) เพื่อดำเนินการทดลองทางคลินิกระยะที่ 2 ของยา BB-101</title>
		<link>https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b7%e0%b9%88%e0%b8%99%e0%b8%82%e0%b8%ad%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%8d%e0%b8%b2%e0%b8%95%e0%b8%95%e0%b9%88%e0%b8%ad%e0%b8%ad%e0%b8%87%e0%b8%84%e0%b9%8c%e0%b8%81%e0%b8%b2%e0%b8%a3-2/</link>
		
		<dc:creator><![CDATA[agent30]]></dc:creator>
		<pubDate>Sun, 01 Jan 2023 04:00:52 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.morcept.tw/?p=1780</guid>

					<description><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing eli [&#8230;]</p>
<p>The post <a href="https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b7%e0%b9%88%e0%b8%99%e0%b8%82%e0%b8%ad%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%8d%e0%b8%b2%e0%b8%95%e0%b8%95%e0%b9%88%e0%b8%ad%e0%b8%ad%e0%b8%87%e0%b8%84%e0%b9%8c%e0%b8%81%e0%b8%b2%e0%b8%a3-2/">ยื่นขออนุญาตต่อองค์การอาหารและยาของสหรัฐอเมริกา (US FDA) เพื่อดำเนินการทดลองทางคลินิกระยะที่ 2 ของยา BB-101</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></description>
										<content:encoded><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.</p>
<ul>
<li>In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.</li>
<li>Nullam dictum felis eu pede mollis pretium.</li>
<li>Integer tincidunt.</li>
</ul>
<p>Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.</p>
<blockquote><p>Nam eget dui.</p></blockquote>
<p>Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.</p><p>The post <a href="https://blueblood.com.tw/th/%e0%b8%a2%e0%b8%b7%e0%b9%88%e0%b8%99%e0%b8%82%e0%b8%ad%e0%b8%ad%e0%b8%99%e0%b8%b8%e0%b8%8d%e0%b8%b2%e0%b8%95%e0%b8%95%e0%b9%88%e0%b8%ad%e0%b8%ad%e0%b8%87%e0%b8%84%e0%b9%8c%e0%b8%81%e0%b8%b2%e0%b8%a3-2/">ยื่นขออนุญาตต่อองค์การอาหารและยาของสหรัฐอเมริกา (US FDA) เพื่อดำเนินการทดลองทางคลินิกระยะที่ 2 ของยา BB-101</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>ข้อมูลการทดลองทางคลินิกยืนยันว่า ทั้งสองกลุ่มขนาดยาของ BB-101 ช่วยลดขนาดและความรุนแรงของแผลได้อย่างมีประสิทธิภาพ</title>
		<link>https://blueblood.com.tw/th/%e0%b8%82%e0%b9%89%e0%b8%ad%e0%b8%a1%e0%b8%b9%e0%b8%a5%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%97%e0%b8%94%e0%b8%a5%e0%b8%ad%e0%b8%87%e0%b8%97%e0%b8%b2%e0%b8%87%e0%b8%84%e0%b8%a5%e0%b8%b4%e0%b8%99%e0%b8%b4/</link>
		
		<dc:creator><![CDATA[agent30]]></dc:creator>
		<pubDate>Sat, 01 Oct 2022 04:00:44 +0000</pubDate>
				<category><![CDATA[2025-2021]]></category>
		<category><![CDATA[ข่าวล่าสุด]]></category>
		<guid isPermaLink="false">https://blueblood.morcept.tw/?p=1783</guid>

					<description><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing eli [&#8230;]</p>
<p>The post <a href="https://blueblood.com.tw/th/%e0%b8%82%e0%b9%89%e0%b8%ad%e0%b8%a1%e0%b8%b9%e0%b8%a5%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%97%e0%b8%94%e0%b8%a5%e0%b8%ad%e0%b8%87%e0%b8%97%e0%b8%b2%e0%b8%87%e0%b8%84%e0%b8%a5%e0%b8%b4%e0%b8%99%e0%b8%b4/">ข้อมูลการทดลองทางคลินิกยืนยันว่า ทั้งสองกลุ่มขนาดยาของ BB-101 ช่วยลดขนาดและความรุนแรงของแผลได้อย่างมีประสิทธิภาพ</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></description>
										<content:encoded><![CDATA[<p>Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Donec quam felis, ultricies nec, pellentesque eu, pretium quis, sem. Nulla consequat massa quis enim. Donec pede justo, fringilla vel, aliquet nec, vulputate eget, arcu.</p>
<ul>
<li>In enim justo, rhoncus ut, imperdiet a, venenatis vitae, justo.</li>
<li>Nullam dictum felis eu pede mollis pretium.</li>
<li>Integer tincidunt.</li>
</ul>
<p>Cras dapibus. Vivamus elementum semper nisi. Aenean vulputate eleifend tellus. Aenean leo ligula, porttitor eu, consequat vitae, eleifend ac, enim. Aliquam lorem ante, dapibus in, viverra quis, feugiat a, tellus. Phasellus viverra nulla ut metus varius laoreet. Quisque rutrum. Aenean imperdiet. Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies nisi.</p>
<blockquote><p>Nam eget dui.</p></blockquote>
<p>Etiam rhoncus. Maecenas tempus, tellus eget condimentum rhoncus, sem quam semper libero, sit amet adipiscing sem neque sed ipsum. Nam quam nunc, blandit vel, luctus pulvinar, hendrerit id, lorem. Maecenas nec odio et ante tincidunt tempus. Donec vitae sapien ut libero venenatis faucibus. Nullam quis ante. Etiam sit amet orci eget eros faucibus tincidunt. Duis leo. Sed fringilla mauris sit amet nibh. Donec sodales sagittis magna. Sed consequat, leo eget bibendum sodales, augue velit cursus nunc, quis gravida magna mi a libero. Fusce vulputate eleifend sapien. Vestibulum purus quam, scelerisque ut, mollis sed, nonummy id, metus. Nullam accumsan lorem in dui. Cras ultricies mi eu turpis hendrerit fringilla. Vestibulum ante ipsum primis in faucibus orci luctus et ultrices posuere cubilia Curae; In ac dui quis mi consectetuer lacinia. Nam pretium turpis et arcu. Duis arcu tortor, suscipit eget, imperdiet nec, imperdiet iaculis, ipsum.</p><p>The post <a href="https://blueblood.com.tw/th/%e0%b8%82%e0%b9%89%e0%b8%ad%e0%b8%a1%e0%b8%b9%e0%b8%a5%e0%b8%81%e0%b8%b2%e0%b8%a3%e0%b8%97%e0%b8%94%e0%b8%a5%e0%b8%ad%e0%b8%87%e0%b8%97%e0%b8%b2%e0%b8%87%e0%b8%84%e0%b8%a5%e0%b8%b4%e0%b8%99%e0%b8%b4/">ข้อมูลการทดลองทางคลินิกยืนยันว่า ทั้งสองกลุ่มขนาดยาของ BB-101 ช่วยลดขนาดและความรุนแรงของแผลได้อย่างมีประสิทธิภาพ</a> first appeared on <a href="https://blueblood.com.tw">寶血純化科技-BLUE BLOOD</a>.</p>]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
